Clinical Trials Browser

Phase 1/2 × Mesothelioma, Malignant × Gastrointestinal × Clear all

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Mesothelioma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Recurrence, Colorectal Neoplasms

NCT05795595 2025-11-26

A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors

Phase 1/2 Completed

19 enrolled

GastrointestinalGenitourinaryGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms

NCT06603987 2025-11-19

Using CICS-1 and SPM-011 and ［18F］FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA

Phase 1/2 Enrolling by invitation

30 enrolled

BreastGastrointestinalOther solid neoplasmSarcomaThoracic

Mesothelioma, Malignant, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Neurofibrosarcoma

NCT06362369 2025-09-17

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

Phase 1/2 Recruiting

126 enrolled

DermatologicGastrointestinalGenitourinaryOther solid neoplasmThoracic

Turcot syndrome, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Kidney Neoplasms, Liver Neoplasms, Melanoma, Neoplasm Metastasis, Skin Neoplasms, Colorectal Neoplasms

NCT03907852 2025-08-27

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

Phase 1/2 Active not recruiting

57 enrolled

GastrointestinalGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Cholangiocarcinoma

NCT05451849 2025-08-27

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

Phase 1/2 Active not recruiting

6 enrolled

BreastGastrointestinalGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT05714553 2025-07-18

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

Phase 1/2 Terminated

19 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Esophageal Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05086692 2025-07-09

ABILITY-1

Phase 1/2 Recruiting

115 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Mesothelioma, Malignant, Urinary Bladder Neoplasms, Carcinoma, Basal Cell, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Fallopian Tube Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Skin Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05944237 2025-06-08

HTL0039732 in Participants With Advanced Solid Tumours

Phase 1/2 Recruiting

150 enrolled

EndocrineGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmSarcomaThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Neoplasms, Pancreatic Neoplasms, Pheochromocytoma, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT05500508 2024-12-24

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

Phase 1/2 Terminated

15 enrolled

BreastCNSDermatologicEndocrineGastrointestinalGynecologicHead & NeckOther solid neoplasmThoracic

Thyroid Cancer, Papillary, Diffuse Intrinsic Pontine Glioma, Mesothelioma, Malignant, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioma, Head and Neck Neoplasms, Melanoma, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT01291420 2024-12-09

Dendritic Cell Vaccination for Patients with Solid Tumors

Phase 1/2 Completed

48 enrolled

BreastCNSGastrointestinalGenitourinaryOther solid neoplasmSarcomaThoracic

Mesothelioma, Malignant, Breast Neoplasms, Carcinoma, Renal Cell, Glioblastoma, Sarcoma, Colorectal Neoplasms

NCT03233724 2023-05-31

Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas

Phase 1/2 Terminated

9 enrolled 14 charts

GastrointestinalOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Lung Neoplasms

NCT03475953 2023-03-03

REGOMUNE

Phase 1/2 Unknown

747 enrolled

BreastEndocrineGastrointestinalGenitourinaryHead & NeckNETOther solid neoplasmSarcomaThoracic

Gastro-enteropancreatic neuroendocrine tumor, Turcot syndrome, Tertiary Lymphoid Structures, Mesothelioma, Malignant, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Thyroid Neoplasms, Triple Negative Breast Neoplasms

Clinical Trials

EVEREST-2

A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors

Using CICS-1 and SPM-011 and ［18F］FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

ABILITY-1

HTL0039732 in Participants With Advanced Solid Tumours

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

Dendritic Cell Vaccination for Patients with Solid Tumors

Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas

REGOMUNE